Pathologic complete response after neoadjuvant paclitaxel and carboplatin chemotherapy for stage II-III breast cancer: A community cancer center experience.

被引：0
|
作者：
Belur, Anuradha
Raajasekar, Arun Kumar Arumugam
Burdette-Radoux, Susan
机构：
[1] Maimonides Canc Ctr, Brooklyn, NY USA
[2] Maimonides Hosp, Brooklyn, NY 11219 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期
关键词：
D O I：
10.1200/jco.2015.33.28_suppl.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients without pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer
    Burdette-Radoux, Susan
    Holmes, Chris E.
    Khan, Farrah B.
    Dittus, Kim
    Wilson, Karen M.
    Wood, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [32] Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer
    Singletary, SE
    AMERICAN JOURNAL OF SURGERY, 2001, 182 (04): : 341 - 346
  • [33] Predictors of pathological complete response to neoadjuvant chemotherapy in stage II and III breast cancer: The impact of chemotherapeutic regimen
    Nwaogu, Iheoma Y.
    Fayanju, Oluwadamilola M.
    Jeffe, Donna B.
    Margenthaler, Julie A.
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 1117 - 1122
  • [34] Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer
    Chakravarthy, AB
    Kelley, MC
    McLaren, B
    Truica, CI
    Billheimer, D
    Mayer, IA
    Grau, AM
    Johnson, DH
    Simpson, JF
    Beauchamp, RD
    Jones, C
    Pietenpol, JA
    CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1570 - 1576
  • [35] Pathologic Complete Response (pCR) in Breast Cancer Patients After Neoadjuvant Chemotherapy at a Comprehensive Cancer Center: The Natural History of an Elusive Prognosticator
    Fayanju, Oluwadamilola M.
    Nwaogu, Iheoma
    Jeffe, Donna B.
    Margenthaler, Julie A.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 49 - 49
  • [36] Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel
    Shinde, Arvind Manohar
    Yim, John H.
    Kruper, Laura
    Vito, Courtney
    Chen, Steven L.
    Paz, Isaac Benjamin
    Luu, Thehang H.
    Tagawa, Tomoko
    Yu, Kim Wai
    Wilczynski, Sharon
    Shaw, Sally
    Vora, Lalit
    Park, Jinha Mark
    Somlo, George
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Surgical aspects of induction chemotherapy in stage II-III breast cancer
    Terribile, D
    Masetti, R
    Marra, A
    Antinori, A
    Valentini, M
    Margaritora, S
    Nardone, L
    Scapati, AM
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1043 - 1043
  • [38] High complete response rate with a novel neoadjuvant chemoradiation regimen for stage II-III esophageal cancer
    Nieuwenhuijzen, G. A.
    Van der Schoot, L.
    Creemers, G. J.
    Van der Sangen, M.
    van Driel, O. J. Repelaer
    Rutten, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 17 - 17
  • [39] Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer
    Jae-Heon Jeong
    So-Youn Jung
    In Hae Park
    Keun Seok Lee
    Han-Sung Kang
    Seok Won Kim
    Youngmee Kwon
    Eun A Kim
    Kyung Lan Ko
    Byung-Ho Nam
    Seeyoun Lee
    Jungsil Ro
    Investigational New Drugs, 2012, 30 : 408 - 416
  • [40] Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer
    Jeong, Jae-Heon
    Jung, So-Youn
    Park, In Hae
    Lee, Keun Seok
    Kang, Han-Sung
    Kim, Seok Won
    Kwon, Youngmee
    Kim, Eun A.
    Ko, Kyung Lan
    Nam, Byung-Ho
    Lee, Seeyoun
    Ro, Jungsil
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 408 - 416
12345